



The role of regulatory B cells in allergen immunotherapy

van de Veen, Willem

Abstract: PURPOSE OF REVIEW Allergen immunotherapy (AIT) is currently the only curative treatment available for allergic diseases, and has been used in clinical practice for over a century. Induction and maintenance of immune tolerance to nonhazardous environmental and self-antigens is essential to maintain homeostasis and prevent chronic inflammation. Regulatory B (BREG) cells are immunoregulatory cells that protect against chronic inflammatory responses primarily through production of anti-inflammatory cytokines such as IL-10, transforming growth factor- β , and IL-35. The importance of BREG cells has been extensively demonstrated in the context of autoimmune diseases. Data showing their role in the regulation of allergic responses are slowly accumulating. This review summarizes recent findings relevant to the topic of BREG cells and their potential role in AIT. RECENT FINDINGS BREG cells support AIT in models of allergic airway inflammation and intestinal inflammation through induction of regulatory T (TREG) cells. In humans BREG frequency increases during venom immunotherapy while the phenotype of allergen-specific B cells changes. Mechanisms of BREG-mediated tolerance to allergens include IL-10-mediated suppression of effector T cell, including TH2 responses, induction of TREG cells, IL-10-mediated inhibition of Dendritic cell maturation, modulation of T follicular helper responses, and production of anti-inflammatory IgG4 antibodies. SUMMARY Current evidence supports a potential role for BREG cells in induction and maintenance of allergen tolerance during AIT. A better understanding of the role of B cells and BREG cells in AIT could open potential new windows for developing targeted therapies specifically focused on promoting BREG responses during AIT.

DOI: <https://doi.org/10.1097/ACI.0000000000000400>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-145834>

Journal Article

Published Version

Originally published at:

van de Veen, Willem (2017). The role of regulatory B cells in allergen immunotherapy. *Current Opinion in Allergy and Clinical Immunology*, 17(6):447-452.

DOI: <https://doi.org/10.1097/ACI.0000000000000400>



The role of regulatory B cells in allergen immunotherapy

Willem van de Veen^{a,b}

Purpose of review

Allergen immunotherapy (AIT) is currently the only curative treatment available for allergic diseases, and has been used in clinical practice for over a century. Induction and maintenance of immune tolerance to nonhazardous environmental and self-antigens is essential to maintain homeostasis and prevent chronic inflammation. Regulatory B (B_{REG}) cells are immunoregulatory cells that protect against chronic inflammatory responses primarily through production of anti-inflammatory cytokines such as IL-10, transforming growth factor-β, and IL-35. The importance of B_{REG} cells has been extensively demonstrated in the context of autoimmune diseases. Data showing their role in the regulation of allergic responses are slowly accumulating. This review summarizes recent findings relevant to the topic of B_{REG} cells and their potential role in AIT.

Recent findings

B_{REG} cells support AIT in models of allergic airway inflammation and intestinal inflammation through induction of regulatory T (T_{REG}) cells. In humans B_{REG} frequency increases during venom immunotherapy while the phenotype of allergen-specific B cells changes. Mechanisms of B_{REG}-mediated tolerance to allergens include IL-10-mediated suppression of effector T cell, including T_{H2} responses, induction of T_{REG} cells, IL-10-mediated inhibition of Dendritic cell maturation, modulation of T follicular helper responses, and production of anti-inflammatory IgG4 antibodies.

Summary

Current evidence supports a potential role for B_{REG} cells in induction and maintenance of allergen tolerance during AIT. A better understanding of the role of B cells and B_{REG} cells in AIT could open potential new windows for developing targeted therapies specifically focused on promoting B_{REG} responses during AIT.

Keywords

allergen immunotherapy, allergy, regulatory B, IL-10, tolerance

INTRODUCTION

Allergen immunotherapy (AIT) has been used as a curative treatment for allergies for more than a century and many of its underlying mechanisms have been elucidated. These include early desensitization of mast cells and basophils, induction of Regulatory T (T_{REG}) cells, production of allergen-specific IgG (particularly IgG4) antibodies, suppression of eosinophil activation and migration [1,2]. In addition, several recent studies suggest a potential role for regulatory B (B_{REG}) cells in AIT [3].

PHENOTYPE AND FUNCTION OF REGULATORY B CELLS

B_{REG} cells exhibit anti-inflammatory functions, and their immunosuppressive role has been demonstrated to varying degrees in autoimmune disease, cancer, transplantation, infection, and allergic inflammation [3,4].

SUPPRESSIVE MECHANISMS OF REGULATORY B CELLS

B_{REG} cells act primarily through secretion of the immune-modulatory cytokines [3]. Most studies have focused on the role of IL-10 as the key factor through which B_{REG} cells modulate immune responses and protect against excessive inflammation [5–10]. IL-10 has a wide range of suppressive effects on different cells types and has been widely recognized as an immune tolerance-inducing factor

^aSwiss Institute of Allergy and Asthma Research, University of Zürich, Davos and ^bChristine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland

Correspondence to Willem van de Veen, PhD, Swiss Institute of Allergy and Asthma Research, Obere Strasse 22, CH-7270, Davos, Switzerland. Tel: +41 0 81 410 08 44; e-mail: willem.vandeven@siaf.uzh.ch

Curr Opin Allergy Clin Immunol 2017, 17:447–452

DOI:10.1097/ACI.0000000000000400

KEY POINTS

- Current evidence supports a potential role for B_{REG} cells in induction and maintenance of allergen tolerance.
- IL-10-producing B_{REG} cells expand during AIT in murine models of allergic airway and intestinal inflammation, as well as in human VIT.
- B_{REG} cells may contribute to tolerance induction during AIT include IL-10-mediated suppression of effector T cell, including T_{H2} responses, induction of T_{REG} cells, IL-10-mediated inhibition of DC maturation, modulation of T_{FH} responses, and production of anti-inflammatory IgG4 antibodies.

in patients with different chronic inflammatory diseases [11]. Transforming growth factor- β (TGF- β) has also been identified as B_{REG}-associated suppressor molecule. TGF- β is involved in many processes including tissue remodelling and immune regulation. An important role for TGF- β in the context of immune tolerance is its capacity to support conversion of naive CD4⁺ T cells to T_{REG} cells [11]. Finally, IL-35 has also been linked to B_{REG}-mediated immune suppression [12]. IL-35 can promote immune tolerance through induction of T_{REG} proliferation and suppression of T_{H17} responses [11].

Apart from secreted cytokines, other molecules have been associated with B_{REG}-mediated suppressive effects. These include the membrane-associated molecules such as CD19 [13], CD62L and MHC-II [14], fas ligand [15], T-cell immunoglobulin and mucin domain [16], and programmed death ligand 1 [8,17–20], as well as the intracellular signalling molecules signal transducer and activator of transcription 3 and myeloid differentiation response gene 88 [21].

In the context of human allergen tolerance induction, the production of IgG4 antibodies deserves some attention. IgG4 is considered to compete with IgE for allergen binding and therefore may function as a blocking antibody. Some unique features of IgG4 such as antigen-binding fragment-arm exchange, its low affinity for activating fragment crystallizable receptors, and its inability to fix complement render IgG4 an anti-inflammatory immunoglobulin isotype [22,23].

One of the mechanisms through which B_{REG} cells could play a role in AIT, is through the modulation of T-cell responses. B_{REG} cells have been shown to induce T_{REG} cells in several different models [3,24,25]. Apart from induction of T_{REG} cells, B_{REG} cells could support AIT through suppression of effect T-cell proliferation and cytokine production [8,26]. A recent study provided compelling data

demonstrating that B_{REG} cells could modulate T follicular helper (T_{FH}) cell responses. Cocultures of in-vitro generated human T_{FH} cells with B cells resulted (as expected) in plasma cell and memory cell differentiation. Upon addition of B cells that were stimulated for 3 days with CD40L and TLR9-ligand CpG2006 (these cells were considered B_{REG} in this study), the B-cell differentiation was inhibited, and forkhead box (FoxP)3⁺C-X-C chemokine receptor (CXCR)5⁺ programmed death ligand-1⁺ regulatory T_{FH} were expanded. CD40, CD80, CD86, as well as IL-10 and TGF- β played a role in this process. These findings suggest that B_{REG} cells can interfere with germinal centre reactions through modulation of T_{FH} cells [27^{*}]. A weakness in this study is the fact that stimulated total B cells were used as B_{REG}, whereas only a fraction of these cells can be considered B_{REG} cells. Some of these findings were corroborated in a murine cardiac transplantation model, in which marginal zone B-cell-derived IL-10 proved essential for induction of regulatory T_{FH} cells and tolerance toward the allograft [28].

DIFFERENT SUBSETS OF REGULATORY B CELLS

A number of different human and murine B_{REG} cells have been identified based on phenotypic and functional characteristics. It goes beyond the scope of this review to describe all B_{REG} subsets in detail and comprehensive reviews on this topic have been published elsewhere [3,4]. In the mouse system, B_{REG} cells are found among cells with a B1a-like cells (i.e. CD5⁺ B cells) [29], among B cells with an immature/transitional phenotype [30,31], and among cells with a plasma cell phenotype [32]. In the human system, the major phenotypes of B_{REG} cells are CD27⁺CD24^{hi}CD148^{hi}CD48^{hi} B10/pro-B10 cells [18], CD24^{hi}CD38^{hi} immature B cells [20], CD73⁻CD25⁺CD71⁺ type 1 regulatory B (B_{R1}) cells, and CD27^{int}CD38^{+/hi} plasmablasts [3,17,32].

REGULATORY B CELLS AND THEIR ROLE IN TOLERANCE INDUCTION TO ALLERGENS

The majority of studies on B_{REG} cells have focused on their role in autoimmune diseases. However, an increasing body of evidence supports a potential role for B_{REG} cells in maintaining and restoring tolerance to allergens. Several recent studies provide support for a role for B_{REG} cells in AIT. Mechanisms through which B_{REG} cells could support AIT include induction of T_{REG} cells, direct suppression of effector T cells, indirect suppression of effector T cells through inhibition of Dendritic cell (DC)

maturation, and production of IgG4 antibodies. Studies focusing on mouse models of allergic disease, primarily demonstrated a role for B_{REG} cells with a B1a-like phenotype [10,26,33], whereas human studies focused on allergic disease primarily reported on B_{R1} cells [8,34[■],35].

REGULATORY B CELLS IN INDUCTION AND MAINTENANCE OF TOLERANCE TO ALLERGENS IN HUMANS

The aim of AIT is typically to restore clinical and immunological tolerance to allergens [36]. This requires the alteration of a T_{H2} and IgE-dominated allergic response toward a healthy immune response. Healthy immune responses to allergens have been studied primarily in cat owners and beekeepers. Hallmarks of a healthy response to allergens are induction of IL-10-producing inducible type 1 regulatory T (T_{R1}) cells and blocking IgG(4) antibodies [37].

A human B_{REG} subset that has been studied in the context of tolerance to allergens are CD73⁻CD24⁺CD71⁺ B_{R1} cells [8]. These cells could efficiently suppress antigen-specific CD4⁺ T-cells proliferation. Data supporting a role for human B_{REG} cells in developing tolerance to allergens comes primarily from studies on bee venom allergic individuals and healthy beekeepers. B cells specific for the major bee venom allergen phospholipase A2 (PLA) were identified using fluorescently labelled PLA. The frequency of IL-10-producing B cells among these allergen-specific B cells showed a two to five-fold increase in bee venom allergic patients at 3–4 months after the start of venom immunotherapy (VIT). After this increase the frequency of PLA-specific IL-10-producing B cells was at a comparable level as in healthy beekeepers during the season [8]. It remains to be elucidated whether allergen-specific B cells upregulate IL-10 production during VIT, or preexisting IL-10-producing allergen-specific B cells proliferate during VIT. Apart from IL-10, allergen-specific B cells also upregulated C-C chemokine receptor (CCR)5, a receptor for Macrophage Inflammatory Protein 1 α and β as well as regulated on activation, normal T cell expressed and secreted, during VIT [34[■]]. Although CCR5 expressed on T_{REG} cells has been found to mediate their migration to inflammatory sites [38], its function on allergen-specific B_{REG} cells remains to be determined.

The frequency of circulating allergen-specific B cells has been shown to increase during peanut immunotherapy and VIT [34[■],39,40[■]]. A fraction of these cells may be IL-10⁺ allergen-specific B cells [8]. In accordance with increases in serum levels of

allergen specific IgG4 of that are frequently observed during AIT [36], it was primarily expansion of allergen-specific IgG4-switched B cells that drove this increase of allergen-specific B cells during VIT [34[■]]. Increases in specific IgG4 during AIT correlate with clinical outcome in some, but not all studies [36]. One intriguing possibility is that not just an increase of specific IgG4 is sufficient for clinical improvement but rather the generation of high-affinity-specific IgG4 antibodies. This concept is technically challenging to prove, but recent work indicates that IgG4 (but not IgE)-switched peanut allergen-specific B cells accumulate an increasing proportion of more highly mutated sequences over time during the course of peanut oral immunotherapy [40[■]]. As increased levels of somatic mutations are indicative of affinity maturation [41], these data suggest that IgG4 antibodies increase their affinity during AIT.

Very interesting in the context of a potential role for B_{REG} cells during AIT is the link between IL-10-producing B_{R1} cells and IgG4 production. Purified IL-10-producing B cells produced significantly increased levels of IgG4 antibodies compared to IL-10⁻ B cells, whereas other immunoglobulin isotypes were produced in comparable amounts by IL-10⁺ and IL-10⁻ cells [8]. Thus, B_{R1} may promote allergen tolerance during AIT through IL-10-mediated suppressive effects and through directing the humoral response toward IgG4.

REGULATORY B CELLS IN MOUSE MODELS OF TOLERANCE INDUCTION IN ALLERGIC AIRWAY INFLAMMATION

B cells can induce allergen tolerance through production of TGF- β as was demonstrated in an ovalbumin (OVA)-induced airway inflammation and tolerance model. Mice that were administered a short-term (7 day) daily intranasal OVA exposure developed sensitization, whereas chronically exposed mice (42-day exposure) developed tolerance. Adoptively transferred B cells isolated from hilar lymph nodes of chronically exposed mice suppressed allergic airway inflammation in sensitized recipient mice. This suppressive effect was independent of IL-10, as B cells isolated from tolerant IL-10^{-/-} mice exerted similar suppressive capacity [42]. Later it was found that CD5⁺CD1d^{hi} B cells were expanded in hilar lymph nodes of tolerant mice. These cells produced TGF- β and induced FoxP3 expression in CD4⁺ T cells *in vitro* and suppressed development of allergic airway inflammation *in vivo* via enhanced accumulation of Foxp3⁺ T cells in the lung [24].

A recent study with a different approach demonstrated that development of OVA-induced airway

inflammation and tolerance induction were developed similarly in wild-type (WT) and B cell-deficient (μ MT) mice, indicating that B cells are not required for establishing OVA-induced airway inflammation. Tolerance could be induced by pretreatment with a high dose of intranasally administered OVA both in WT and μ MT mice, suggesting that B cells were dispensable for tolerance induction in this model. IL-10 production by purified splenic B cells in response to lipopolysaccharide stimulation from OVA-sensitized and tolerized showed a similar and modest increase compared with control mice [25]. The effect of TGF- β production was not assessed in this study. It is interesting to note here that OVA-induced airway inflammation was accompanied by elevated germinal centre B cells numbers and elevated specific immunoglobulin production, whereas these B cell alterations were attenuated upon tolerance induction. Moreover, marginal zone

precursor B cells from tolerant mice could induce T_{REG} cells *in vitro* [25].

Methodological differences (e.g. application routes, dosing schemes, B cell-deficient mice vs. adoptive transfer experiments) may partially explain the seemingly different conclusions of these studies. However, taken together these datapoint out that in high-dose OVA tolerance induction models for allergic airway inflammation, B_{REG} cells can be induced or expanded. These B_{REG} cells have the capacity to induce T_{REG} cells and, upon adoptive transfer, confer allergen tolerance in sensitized recipient mice in an IL-10-independent manner. TGF- β could be the driving factor in this process. These B_{REG} cells may therefore contribute to allergen-tolerance induction in such an AIT model but the fact that B cell-deficient mice still develop tolerance indicates that there is redundancy with other suppressor cells.




FIGURE 1. Mechanisms of B_{REG}-mediated immunoregulation during AIT. IL-10 and TGF- β can be produced by B_{REG} cells. IL-10 can suppress effector T-cell responses directly but also indirectly through suppression of DC maturation. IL-10 produced by B_{REG} cells may promote IgG4 production in an autocrine, as well as a paracrine manner. Both B_{REG} cells can induce T_{REG} cells through IL-10 and TGF- β . AIT, allergen immunotherapy; B_{REG}, regulatory B; TGF, transforming growth factor.

REGULATORY B CELLS IN MOUSE MODELS OF TOLERANCE INDUCTION IN ALLERGIC INTESTINAL INFLAMMATION

Similar to what was found in models of allergic airway inflammation, B-cell-derived TGF- β may play a key role in tolerance induction to food allergens. A fraction of CD5⁺CX3CR1⁺ B cells present in the intestine of naive Bagg albino mice produced TGF- β in response to stimulation with α v β 6 and a B cell receptor (BCR) crosslinking antibody. Intestinal epithelial cells may recruit CD5⁺CX3CR1⁺ B cells, through production of fractalkine, which is a ligand for CXCR3. Food antigen-specific CD5⁺CX3CR1⁺ B cells could form a local source of TGF- β upon encounter of their cognate antigen and epithelial cell-derived α v β 6. Adoptive transfer of CD5⁺CX3CR1⁺ B cells could ameliorate T_H2-mediated intestinal inflammation [26]. A factor that may promote TGF- β production by B cells is thrombospondin 1, which enhances generation of active TGF- β . When mice sensitized with OVA and cholera toxin (to induce intestinal inflammation) received an AIT regimen in the form of increasing doses of gavage-fed OVA, CD35⁺ B cells in the lamina propria increased in frequency and produced thrombospondin 1 [43].

CONCLUSION

AIT has been used with considerable success for over a century. Increasingly detailed knowledge has been accumulated on the immunological mechanisms that drive successful clinical outcome of this therapy. B_{REG} cells have only recently been identified as potentially relevant cells in the induction and maintenance of allergen tolerance. Currently available data suggest potential roles for B_{REG} cells in AIT treatment of allergic airway inflammation, food allergies, and venom allergies. Mechanisms through which B_{REG} cells may contribute to tolerance induction during AIT are summarized in Fig. 1 and include IL-10-mediated suppression of effector T cell, including T_H2 responses [8,26], induction of T_{REG} cells [24,25], IL-10-mediated inhibition of DC maturation [44], modulation of T_{FH} responses [27[■],28], and production of anti-inflammatory IgG4 antibodies [8,34[■]]. A better understanding of the role of B cells and B_{REG} cells in AIT could open up potential windows for developing targeted therapies specifically focused on promoting B_{REG} responses during AIT.

Acknowledgements

None.

Financial support and sponsorship

None.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Soyka MB, van de Veen W, Holzmann D, *et al.* Scientific foundations of allergen-specific immunotherapy for allergic disease. *Chest* 2014; 146: 1347–1357.
2. Jutel M, Agache I, Bonini S, *et al.* International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoconomics. *J Allergy Clin Immunol* 2016; 137:358–368.
3. van de Veen W, Stanic B, Wirz OF, *et al.* Role of regulatory B cells in immune tolerance to allergens and beyond. *J Allergy Clin Immunol* 2016; 138: 654–665.
4. Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. *J Clin Invest* 2017; 127:772–779.
5. Fillatreau S, Sweeney CH, McGeachy MJ, *et al.* B cells regulate autoimmunity by provision of IL-10. *Nat Immunol* 2002; 3:944–950.
6. Mizoguchi A, Mizoguchi E, Takedatsu H, *et al.* Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. *Immunity* 2002; 16:219–230.
7. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. *J Exp Med* 2003; 197:489–501.
8. van de Veen W, Stanic B, Yaman G, *et al.* IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. *J Allergy Clin Immunol* 2013; 131:1204–1212.
9. van der Vlugt LE, Labuda LA, Ozir-Fazalikhani A, *et al.* Schistosomes induce regulatory features in human and mouse CD1d(hi) B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells. *PLoS One* 2012; 7:e30883.
10. Amu S, Saunders SP, Kronenberg M, *et al.* Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. *J Allergy Clin Immunol* 2010; 125:1114.e8–1124.e8.
11. Akdis M, Aab A, Altunbulakli C, *et al.* Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β , and TNF- α : receptors, functions, and roles in diseases. *J Allergy Clin Immunol* 2016; 138:984–1010.
12. Shen P, Roch T, Lampropoulou V, *et al.* IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. *Nature* 2014; 507:366–370.
13. Yanaba K, Bouaziz JD, Matsushita T, *et al.* The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. *J Immunol* 2009; 182:7459–7472.
14. Yoshizaki A, Miyagaki T, DiLillo DJ, *et al.* Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. *Nature* 2012; 491:264–268.
15. Klinker MW, Reed TJ, Fox DA, Lundy SK. Interleukin-5 supports the expansion of fas ligand-expressing killer B cells that induce antigen-specific apoptosis of CD4(+) T cells and secrete interleukin-10. *PLoS One* 2013; 8:e70131.
16. Ding Q, Yeung M, Camirand G, *et al.* Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. *J Clin Invest* 2011; 121:3645–3656.
17. Shalpour S, Font-Burgada J, Di Caro G, *et al.* Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. *Nature* 2015; 521:94–98.
18. Iwata Y, Matsushita T, Horikawa M, *et al.* Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. *Blood* 2011; 117:530–541.
19. Khan AR, Amu S, Saunders SP, Fallon PG. The generation of regulatory B cells by helminth parasites. *Methods Mol Biol* 2014; 1190:143–162.
20. Blair PA, Norena LY, Flores-Borja F, *et al.* CD19(+)/CD24(hi)/CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. *Immunity* 2010; 32:129–140.
21. Neves P, Lampropoulou V, Calderon-Gomez E, *et al.* Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during *Salmonella typhimurium* infection. *Immunity* 2010; 33:777–790.
22. van de Veen W, Akdis M. Role of IgG4 in IgE-mediated allergic responses. *J Allergy Clin Immunol* 2016; 138:1434–1435.
23. Aalberse RC, Platts-Mills TA, Rispens T. The developmental history of IgE and IgG4 antibodies in relation to atopy, eosinophilic esophagitis, and the modified TH2 response. *Curr Allergy Asthma Rep* 2016; 16:45.

24. Natarajan P, Singh A, McNamara JT, *et al.* Regulatory B cells from hilar lymph nodes of tolerant mice in a murine model of allergic airway disease are CD5⁺, express TGF- β , and co-localize with CD4⁺Foxp3⁺ T cells. *Mucosal Immunol* 2012; 5:691–701.
25. Habener A, Behrendt AK, Skuljec J, *et al.* B cell subsets are modulated during allergic airway inflammation but are not required for the development of respiratory tolerance in a murine model. *Eur J Immunol* 2017; 47:552–562.
26. Liu ZQ, Wu Y, Song JP, *et al.* Tolerogenic CX3CR1⁺ B cells suppress food allergy-induced intestinal inflammation in mice. *Allergy* 2013; 68:1241–1248.
27. Achour A, Simon C, Mohr A, *et al.* Human regulatory B cells control the TFH cell response. *J Allergy Clin Immunol* 2017; 140:215–222. The study provides compelling evidence for B_{REG}-mediated control of T_{FH} responses.
28. Lal G, Kulkarni N, Nakayama Y, *et al.* IL-10 from marginal zone precursor B cells controls the differentiation of Th17, Tfh and Tfr cells in transplantation tolerance. *Immunology Lett* 2016; 170:52–63.
29. Yanaba K, Bouaziz JD, Haas KM, *et al.* A regulatory B cell subset with a unique CD1dhiCD5⁺ phenotype controls T cell-dependent inflammatory responses. *Immunity* 2008; 28:639–650.
30. Evans JG, Chavez-Rueda KA, Eddaoudi A, *et al.* Novel suppressive function of transitional 2 B cells in experimental arthritis. *J Immunol* 2007; 178:7868–7878.
31. Blair PA, Chavez-Rueda KA, Evans JG, *et al.* Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. *J Immunol* 2009; 182:3492–3502.
32. Matsumoto M, Baba A, Yokota T, *et al.* Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. *Immunity* 2014; 41:1040–1051.
33. Khan AR, Amu S, Saunders SP, *et al.* Ligand of TLR7 on CD19(+) CD1d(hi) B cells suppresses allergic lung inflammation via regulatory T cells. *Eur J Immunol* 2015; 45:1842–1854.
34. Boonpiyathad T, Meyer N, Moniuszko M, *et al.* High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers. *Allergy* 2017; 72:407–415. The study demonstrates that allergen-specific B cells expand during AIT and acquire an immunoregulatory phenotype.
35. Kim AS, Doherty TA, Karta MR, *et al.* Regulatory B cells and T follicular helper cells are reduced in allergic rhinitis. *J Allergy Clin Immunol* 2016; 138:1192.e5–1195.e5.
36. Shamji MH, Kappen JH, Akdis M, *et al.* Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI position paper. *Allergy* 2017; 72:1156–1173.
37. Akdis CA, Akdis M. Advances in allergen immunotherapy: aiming for complete tolerance to allergens. *Sci Transl Med* 2015; 7:280ps6.
38. Wysocki CA, Jiang Q, Panoskaltis-Mortari A, *et al.* Critical role for CCR5 in the function of donor CD4⁺CD25⁺ regulatory T cells during acute graft-versus-host disease. *Blood* 2005; 106:3300–3307.
39. Patil SU, Ogunniyi AO, Calatroni A, *et al.* Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects. *J Allergy Clin Immunol* 2015; 136:125.e12–134.e12.
40. Hoh RA, Joshi SA, Liu Y, *et al.* Single B-cell deconvolution of peanut-specific antibody responses in allergic patients. *J Allergy Clin Immunol* 2016; 137:157–167. The study provides a detailed analysis of the development of the allergen-specific BCR variable sequences during peanut oral immunotherapy.
41. Cirelli KM, Crotty S. Germinal center enhancement by extended antigen availability. *Curr Opin Immunol* 2017; 47:64–69.
42. Singh A, Carson WF, Secor ER Jr, *et al.* Regulatory role of B cells in a murine model of allergic airway disease. *J Immunol* 2008; 180:7318–7326.
43. Zhang HP, Wu Y, Liu J, *et al.* TSP1-producing B cells show immune regulatory property and suppress allergy-related mucosal inflammation. *Sci Rep* 2013; 3:3345.
44. Stanic B, van de Veen W, Wirz OF, *et al.* IL-10-overexpressing B cells regulate innate and adaptive immune responses. *J Allergy Clin Immunol* 2015; 135:771.e8–780.e8.